Mark A Glickman Sells $2.17K of TherapeuticsMD Inc (TXMD) — SEC Form 4, Dec 09, 2022

Open-Market Net Sale · SEC Form 4

−$2,165

Equity position changed by +294.1%

Reporting Owner

Mark A Glickman

CEO

TXN 2022-12-06 · FILED 2022-12-09

Equity Position 1.73K sh 440 → 1,734

Equity Change +294.1% shares held after vs before

Filing Lag 3 business days late vs 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

TherapeuticsMD Inc

TXMD CIK 0000025743

Reporting Owner

Name	Relationship
Mark A Glickman CIK 0001441461	CEO

Mark A Glickman at TherapeuticsMD Inc Full insider history

Bought (12 mo) —

Sold (12 mo) —

More from this insider at TherapeuticsMD Inc

Non-Derivative Securities Transactions

Title	Date	Type	Shares	Price	Net Total	Post-Txn	Ownership
Common StockF1	2022-12-06	M - Exercise	1,734 A	$0.00	—	1,734	Direct
Common StockF2	2022-12-06	S - Sale	440 D	$4.92	-$2,165	1,294	Direct

Derivative Securities Transactions

Title	Strike	Date	Type	Shares	Price	Expiration	Underlying	Ownership
Restricted Stock UnitsF1 F3 F3	$0.00	2022-12-06	M - Exercise	1,734 D	$0.00		1,734 Common Stock	Direct

Footnotes (3)

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 1,734 shares of issuer common stock in settlement of restricted stock units (RSUs). Show more
F2: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations Show more
F3: The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer. Show more

Institutional Holders

Largest by reported value

5%+ Holders · 13D/G 2 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at TherapeuticsMD Inc

GET /v1/forms/4/0001209191-22-060586 API docs